奥泰生物调整募投项目资金用途并启动股份回购计划

Project Progress - The company announced the completion of the "Marketing Network Center Construction Project" and the "Hangzhou Aokai Biological Annual Production of 400 Million In Vitro Diagnostic Reagents R&D Center Construction Project," resulting in approximately 210 million yuan of surplus raised funds to permanently supplement working capital, optimizing fund efficiency [2] Fund Movements - On January 21, 2026, the company's board approved a share repurchase plan, intending to use 100 to 200 million yuan of over-raised funds for a buyback at a price not exceeding 85 yuan per share, aimed at reducing registered capital. This plan was approved at the extraordinary shareholders' meeting on February 6, 2026, and will be executed within the next 12 months [3] Strategic Advancement - The announcement also disclosed the 2026 annual routine related party transaction plan, totaling 51.3 million yuan, focusing on high-margin areas such as respiratory multiplex testing and pet diagnostics to address industry transformation [4]